Q\u00eb nga miratimi i ila\u00e7it Zolgensma n\u00eb vitin 2019, prodhuesi, kompania Novartis, ka regjistruar gjithsej n\u00ebnt\u00eb raste t\u00eb tumoreve tek pacient\u00ebt e rinj<\/p>\n
Kompania farmaceutike zvicerane Novartis ka raportuar disa raste t\u00eb tumoreve tek f\u00ebmij\u00ebt pas trajtimit t\u00eb tyre me terapin\u00eb gjenike Zolgensma. N\u00eb dy raste, ka prova t\u00eb nj\u00eb lidhjeje t\u00eb drejtp\u00ebrdrejt\u00eb me ila\u00e7in.<\/p>\n
Q\u00eb nga miratimi i ila\u00e7it n\u00eb vitin 2019, kompania ka regjistruar gjithsej n\u00ebnt\u00eb raste t\u00eb tumoreve tek pacient\u00ebt e rinj, transmeton albinfo.ch. N\u00eb dy nga individ\u00ebt e prekur, ekspert\u00ebt zbuluan material gjenetik nga vektori, bart\u00ebsi biologjik i gjenit, n\u00eb ADN. Kompania deklaron se ka informuar n\u00eb m\u00ebnyr\u00eb t\u00eb p\u00ebrshtatshme autoritetet p\u00ebrkat\u00ebse sh\u00ebndet\u00ebsore p\u00ebr k\u00ebto zhvillime.<\/p>\n
Si\u00e7 raportohet nga portali zviceran i lajmeve \u201c20 Minuten\u201d, f\u00ebmij\u00ebt e prekur po marrin kujdes mjek\u00ebsor dhe po monitorohen vazhdimisht.<\/p>\n
Rreziku potencial i formimit t\u00eb tumorit p\u00ebr shkak t\u00eb futjes s\u00eb ADN-s\u00eb vektoriale \u00ebsht\u00eb tashm\u00eb i listuar n\u00eb informacionin e p\u00ebrshkrimit t\u00eb ila\u00e7it. Me nj\u00eb kosto prej af\u00ebrsisht dy milion\u00eb dollar\u00ebsh, Zolgensma konsiderohet si nj\u00eb nga ila\u00e7et m\u00eb t\u00eb shtrenjta n\u00eb bot\u00eb.<\/p>\n
Infuzioni i vet\u00ebm i k\u00ebtij ila\u00e7i synon drejtp\u00ebrdrejt shkaqet e s\u00ebmundjes s\u00eb rrall\u00eb trash\u00ebgimore atrofi muskulore spinale, p\u00ebrcjell albinfo.ch. Pa trajtim efektiv, humbja progresive e forc\u00ebs muskulore tek f\u00ebmij\u00ebt e vegj\u00ebl zakonisht \u00e7on n\u00eb vdekje para dit\u00eblindjes s\u00eb tyre t\u00eb dyt\u00eb.<\/p>\n
Grupi i avokimit t\u00eb pacient\u00ebve k\u00ebrkon sqarime t\u00eb shpejta<\/p>\n
Q\u00eb nga miratimi i tij fillestar, m\u00eb shum\u00eb se 6,000 f\u00ebmij\u00eb n\u00eb t\u00eb gjith\u00eb bot\u00ebn kan\u00eb marr\u00eb terapin\u00eb p\u00ebrmes studimeve ose trajtimeve rutin\u00eb. Organizata e pacient\u00ebve SMA Europe e konsideron numrin e incidenteve t\u00eb raportuara t\u00eb ul\u00ebt. Megjithat\u00eb, grupi i avokimit i b\u00ebri thirrje publikisht kompanis\u00eb farmaceutike t\u00eb ofroj\u00eb informacion.<\/p>\n
Organizata ka \u201ck\u00ebrkuar urgjentisht q\u00eb Novartis t\u00eb ofroj\u00eb informacion mbi at\u00eb q\u00eb dihet, at\u00eb q\u00eb mbetet e paqart\u00eb dhe \u00e7far\u00eb mund t\u00eb n\u00ebnkuptoj\u00eb kjo p\u00ebr f\u00ebmij\u00ebt q\u00eb kan\u00eb marr\u00eb trajtim\u201d.<\/p>\n
Pavar\u00ebsisht rasteve t\u00eb dyshuara t\u00eb raportuara, shoqata e pacient\u00ebve aktualisht k\u00ebshillon kund\u00ebr veprimeve t\u00eb nxituara. Sipas \u201c20 Minuten\u201d, mjek\u00ebt q\u00eb trajtojn\u00eb aktualisht nuk po p\u00ebrballen me ndonj\u00eb ndryshim n\u00eb udh\u00ebzimet e kujdesit pasues.<\/p>\n
Grupi i avokimit sqaron: \u201cBazuar n\u00eb informacionin aktualisht t\u00eb disponuesh\u00ebm, nuk rekomandohen ndryshime n\u00eb kujdesin ose ndjekjen rutin\u00eb t\u00eb f\u00ebmij\u00ebs suaj, dhe aktualisht nuk jan\u00eb t\u00eb nevojshme skanime, teste ose monitorime shtes\u00eb\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"
Q\u00eb nga miratimi i ila\u00e7it Zolgensma n\u00eb vitin 2019, prodhuesi, kompania Novartis, ka regjistruar gjithsej n\u00ebnt\u00eb raste t\u00eb tumoreve tek pacient\u00ebt e rinj Kompania farmaceutike zvicerane Novartis ka raportuar disa raste t\u00eb tumoreve tek f\u00ebmij\u00ebt pas trajtimit t\u00eb tyre me terapin\u00eb gjenike Zolgensma. N\u00eb dy raste, ka prova t\u00eb nj\u00eb lidhjeje t\u00eb drejtp\u00ebrdrejt\u00eb me ila\u00e7in. […]<\/p>\n","protected":false},"author":1,"featured_media":249261,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"tmauthors":[136],"class_list":["post-249260","post","type-post","status-publish","format-standard","has-post-thumbnail","category-shendetesi"],"_links":{"self":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/249260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/comments?post=249260"}],"version-history":[{"count":1,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/249260\/revisions"}],"predecessor-version":[{"id":249262,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/249260\/revisions\/249262"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/media\/249261"}],"wp:attachment":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/media?parent=249260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/categories?post=249260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/tags?post=249260"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/tmauthors?post=249260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}